Wellcare does cover GLP-1 drugs, but only when they are prescribed for an FDA-approved use other than weight loss. On Wellcare’s Medicare Advantage and standalone Part D plans, drugs like Ozempic, Mounjaro, Rybelsus, and Trulicity may be covered for type 2 diabetes; Wegovy may be covered to reduce cardiovascular risk; and Zepbound may be covered for obstructive sleep apnea in adults with obesity. Weight loss by itself is not a covered Part D use. For that, a separate federal program, not Wellcare, pays the claim.
Which GLP-1 Drugs Wellcare Covers
Wellcare uses what it calls indication-specific coverage: the same drug can be approved for one diagnosis and denied for another. The breakdown for 2026:
- Ozempic, Rybelsus, Trulicity, and Victoza may be covered for type 2 diabetes blood sugar control.
- Mounjaro may be covered for type 2 diabetes.
- Wegovy may be covered to reduce the risk of heart attack, stroke, or cardiovascular death in adults with established cardiovascular disease who are overweight or obese. It is not covered for weight loss alone.
- Zepbound may be covered for moderate to severe obstructive sleep apnea in adults with obesity. It is not covered for weight loss alone.
- Saxenda is not covered under Part D at all, because its only FDA-approved use is weight management.{}1Wellcare. Does Medicare Cover Weight Loss Drugs
Bydureon BCise was removed from the 2026 formulary, with Mounjaro, Ozempic, Rybelsus, and Trulicity listed as alternatives.{2Wellcare. Wellcare 2026 Formulary Changes} If Wegovy is prescribed for weight loss rather than cardiovascular risk reduction, the claim is denied as a non-covered use, and Part D cost-sharing protections, including the $2,100 annual out-of-pocket cap, do not apply.{1Wellcare. Does Medicare Cover Weight Loss Drugs}
Specific tier placement depends on the plan and state. Wellcare’s standalone Part D plans use a six-tier structure, and high-cost brand GLP-1s typically sit on Tier 5 (specialty), which carries 25% coinsurance. Specialty-tier drugs are not eligible for tier exceptions to a lower cost-sharing level.{3Wellcare. Wellcare Value Script and Classic PDP Summary of Benefits 2026} Members can confirm exact tier and cost by searching the drug list on Wellcare’s website or calling member services.
Prior Authorization Requirements
Every GLP-1 on Wellcare’s Medicare formulary requires prior authorization. The prescriber has to submit documentation covering three things:
- The specific FDA-approved diagnosis the drug is being prescribed for, not weight loss.
- Recent clinical data such as A1C levels, BMI, cardiovascular disease documentation, or sleep apnea findings.
- Treatment history showing what has already been tried and why it did not work or was not appropriate.
A Wellcare provider bulletin confirmed that the point of prior authorization is to verify the drug is being prescribed for type 2 diabetes, and that these medications are not covered for weight loss, pre-diabetes, type 1 diabetes, or heart disease prevention under the standard Part D benefit.{4Wellcare. Medicare Benefit Updates 2024}
What a Covered GLP-1 Costs on Wellcare Part D
When Wellcare does cover a GLP-1, the out-of-pocket cost moves through the standard Part D phases in 2026:
- Deductible of up to $615 per year. The member pays full price for covered drugs until the deductible is met.
- Initial coverage, where coinsurance applies, often 25% for specialty-tier drugs, until total out-of-pocket spending reaches $2,100 for the year.
- Catastrophic coverage, where the member pays $0 for covered drugs for the rest of the calendar year.{}3Wellcare. Wellcare Value Script and Classic PDP Summary of Benefits 2026
Because GLP-1s are expensive, the first fill of the year can be a large bill. Wellcare offers the Medicare Prescription Payment Plan, which lets members spread drug costs into monthly installments instead of paying a lump sum at the pharmacy.
Weight Loss: Coverage Runs Through a Separate Federal Program
If you want a GLP-1 for weight loss, Wellcare is not the payer. On July 1, 2026, CMS launched the Medicare GLP-1 Bridge, a demonstration running through at least December 31, 2027, that covers certain GLP-1s for weight management at a flat $50 copay per monthly supply.{5CMS. Medicare GLP-1 Bridge}{6Medicare Rights Center. GLP-1 Weight Loss Drug Demonstration Begins July 2026}
The Bridge covers Wegovy (injections and tablets), Zepbound KwikPen, and Foundayo when prescribed for weight reduction. Eligibility is based on BMI:
- BMI of 35 or higher with no additional diagnosis needed.
- BMI of 30 or higher with heart failure (preserved ejection fraction), uncontrolled hypertension, or chronic kidney disease stage 3a or above.
- BMI of 27 or higher with pre-diabetes, prior heart attack, prior stroke, or symptomatic peripheral artery disease.{}5CMS. Medicare GLP-1 Bridge
Three things matter for Wellcare members. First, the Bridge operates entirely outside Part D. CMS designated Humana as the centralized processor for the whole program, so prior authorization requests, claims, and pharmacy payments all flow through Humana’s system, not Wellcare’s. CMS has instructed Part D plans to redirect providers who send Bridge requests to the wrong place.{7AMCP. CMS Releases Frequently Asked Questions on Medicare GLP-1 Bridge} Second, because the program sits outside Part D, the $50 copay does not count toward your Wellcare deductible or the $2,100 out-of-pocket cap, and the Low-Income Subsidy cannot reduce it.{} Third, if you already get a GLP-1 through Wellcare for diabetes or cardiovascular disease, that coverage continues under your plan. The Bridge is only for the weight-loss indication Part D does not cover.{8KFF. What Medicare’s Temporary Program Covering GLP-1s for Obesity Means for Beneficiaries}
Wellcare Medicaid Members
Wellcare also runs Medicaid managed care plans in multiple states, and Medicaid rules on GLP-1s differ sharply from Medicare’s. Federal law does not require state Medicaid programs to cover weight-loss drugs, and as of January 2026, only 13 states provided any Medicaid coverage for GLP-1s for obesity. Every state Medicaid program must cover GLP-1s when prescribed for medically accepted indications like type 2 diabetes, cardiovascular disease, or obstructive sleep apnea, and for children under 21 through the federal EPSDT benefit.{9KFF. Medicaid Coverage of and Spending on GLP-1s}
North Carolina is a working example. NC Medicaid reinstated coverage for GLP-1s for weight management effective December 12, 2025, with Wegovy as the preferred drug and Zepbound and Saxenda as non-preferred options requiring a Wegovy trial first.{10NC DHHS. NC Medicaid Reinstitute Coverage GLP-1s Weight Management} On Wellcare’s NC Medicaid plan, adults need a BMI of 30 or higher, or 27 or higher with a weight-related comorbidity such as hypertension, type 2 diabetes, sleep apnea, cardiovascular disease, or dyslipidemia, and the prior authorization requires structured nutrition and physical activity alongside the medication.{11Wellcare NC. GLP-1 Agents for Obesity Management PA Form} In states that do not cover GLP-1s for obesity, Wellcare Medicaid members can get these drugs only when prescribed for a covered condition like diabetes.
Lower Prices Coming in 2027
The cost of GLP-1s on Wellcare plans is set to drop in 2027. CMS selected Ozempic, Rybelsus, and Wegovy for Medicare drug price negotiation and set a Maximum Fair Price of $274 per 30-day supply effective January 1, 2027.{12340B Report. CMS Unveils 2027 Medicare Drug Price Negotiation MFPs} Under separate agreements with the Trump administration, Novo Nordisk and Eli Lilly agreed to supply Ozempic, Wegovy, Mounjaro, and Zepbound to Medicare at $245 per monthly supply, and CMS has indicated the lower price is expected to take precedence.{13NCPA. CMS Announces MFPs for 15 Drugs to Be Added to Medicare Drug Price Negotiation} For Wellcare members whose coinsurance is a percentage of the drug price, a lower wholesale cost means a lower pharmacy bill.